KR20170016725A - Cosmetic Composion for Anti-oxidation Containing Purified Extract of Red Ginseng Ethanol Extract - Google Patents
Cosmetic Composion for Anti-oxidation Containing Purified Extract of Red Ginseng Ethanol Extract Download PDFInfo
- Publication number
- KR20170016725A KR20170016725A KR1020150110187A KR20150110187A KR20170016725A KR 20170016725 A KR20170016725 A KR 20170016725A KR 1020150110187 A KR1020150110187 A KR 1020150110187A KR 20150110187 A KR20150110187 A KR 20150110187A KR 20170016725 A KR20170016725 A KR 20170016725A
- Authority
- KR
- South Korea
- Prior art keywords
- ethanol
- red ginseng
- extract
- fraction
- aqueous
- Prior art date
Links
- 235000002789 Panax ginseng Nutrition 0.000 title claims abstract description 50
- 239000002537 cosmetic Substances 0.000 title claims abstract description 27
- 239000000469 ethanolic extract Substances 0.000 title claims abstract description 22
- 230000003064 anti-oxidating effect Effects 0.000 title claims description 8
- 239000000284 extract Substances 0.000 title description 39
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 129
- 239000000203 mixture Substances 0.000 claims abstract description 40
- 239000002904 solvent Substances 0.000 claims abstract description 28
- 238000003795 desorption Methods 0.000 claims abstract description 18
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 15
- 239000000243 solution Substances 0.000 claims description 18
- 238000000034 method Methods 0.000 claims description 17
- 201000010099 disease Diseases 0.000 claims description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 12
- 238000000605 extraction Methods 0.000 claims description 11
- 239000007864 aqueous solution Substances 0.000 claims description 10
- 230000036542 oxidative stress Effects 0.000 claims description 9
- 238000002360 preparation method Methods 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 206010012601 diabetes mellitus Diseases 0.000 claims description 3
- 208000010125 myocardial infarction Diseases 0.000 claims description 3
- 206010012289 Dementia Diseases 0.000 claims description 2
- 208000013600 Diabetic vascular disease Diseases 0.000 claims description 2
- 208000031226 Hyperlipidaemia Diseases 0.000 claims description 2
- 208000018737 Parkinson disease Diseases 0.000 claims description 2
- 208000006011 Stroke Diseases 0.000 claims description 2
- 201000009101 diabetic angiopathy Diseases 0.000 claims description 2
- 201000002249 diabetic peripheral angiopathy Diseases 0.000 claims description 2
- 206010015037 epilepsy Diseases 0.000 claims description 2
- 230000009759 skin aging Effects 0.000 claims description 2
- 230000037394 skin elasticity Effects 0.000 claims description 2
- 230000037303 wrinkles Effects 0.000 claims description 2
- 208000013200 Stress disease Diseases 0.000 claims 1
- 239000007854 depigmenting agent Substances 0.000 claims 1
- 235000013402 health food Nutrition 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 238000012423 maintenance Methods 0.000 claims 1
- 230000003078 antioxidant effect Effects 0.000 abstract description 46
- 235000013305 food Nutrition 0.000 abstract description 14
- 235000015872 dietary supplement Nutrition 0.000 abstract description 13
- 238000009472 formulation Methods 0.000 abstract description 13
- 239000002031 ethanolic fraction Substances 0.000 abstract description 12
- 238000004519 manufacturing process Methods 0.000 abstract description 11
- 235000019441 ethanol Nutrition 0.000 description 72
- 239000012141 concentrate Substances 0.000 description 19
- 235000008504 concentrate Nutrition 0.000 description 19
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 19
- 229930182494 ginsenoside Natural products 0.000 description 13
- 239000008213 purified water Substances 0.000 description 11
- 240000004371 Panax ginseng Species 0.000 description 8
- 235000008434 ginseng Nutrition 0.000 description 8
- 229940089161 ginsenoside Drugs 0.000 description 8
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 7
- 235000003140 Panax quinquefolius Nutrition 0.000 description 7
- 239000002245 particle Substances 0.000 description 7
- 230000000694 effects Effects 0.000 description 6
- 239000002994 raw material Substances 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- 239000003963 antioxidant agent Substances 0.000 description 5
- 235000006708 antioxidants Nutrition 0.000 description 5
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 235000012149 noodles Nutrition 0.000 description 5
- 229910052760 oxygen Inorganic materials 0.000 description 5
- 239000001301 oxygen Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- -1 superoxide anion radicals Chemical class 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 238000004807 desolvation Methods 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- 239000000945 filler Substances 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 150000003254 radicals Chemical class 0.000 description 3
- 239000003642 reactive oxygen metabolite Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 230000002292 Radical scavenging effect Effects 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 235000008429 bread Nutrition 0.000 description 2
- 235000014121 butter Nutrition 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 239000007902 hard capsule Substances 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 235000021067 refined food Nutrition 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 229930182490 saponin Natural products 0.000 description 2
- 150000007949 saponins Chemical class 0.000 description 2
- 239000007901 soft capsule Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 229920000945 Amylopectin Polymers 0.000 description 1
- 208000031404 Chromosome Aberrations Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 206010067477 Cytogenetic abnormality Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 239000011703 D-panthenol Substances 0.000 description 1
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 description 1
- 235000004866 D-panthenol Nutrition 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 108010082495 Dietary Plant Proteins Proteins 0.000 description 1
- 239000004278 EU approved seasoning Substances 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010014970 Ephelides Diseases 0.000 description 1
- 240000008620 Fagopyrum esculentum Species 0.000 description 1
- 235000009419 Fagopyrum esculentum Nutrition 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 108010063907 Glutathione Reductase Proteins 0.000 description 1
- 102100036442 Glutathione reductase, mitochondrial Human genes 0.000 description 1
- 244000017020 Ipomoea batatas Species 0.000 description 1
- 235000002678 Ipomoea batatas Nutrition 0.000 description 1
- 239000002211 L-ascorbic acid Substances 0.000 description 1
- 235000000069 L-ascorbic acid Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000003351 Melanosis Diseases 0.000 description 1
- 244000294411 Mirabilis expansa Species 0.000 description 1
- 235000015429 Mirabilis expansa Nutrition 0.000 description 1
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 206010059516 Skin toxicity Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 206010042496 Sunburn Diseases 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 108010093894 Xanthine oxidase Proteins 0.000 description 1
- 102100033220 Xanthine oxidase Human genes 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000013527 bean curd Nutrition 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000006189 buccal tablet Substances 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 235000013574 canned fruits Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000007963 capsule composition Substances 0.000 description 1
- 150000001765 catechin Chemical class 0.000 description 1
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 1
- 235000005487 catechin Nutrition 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000001055 chewing effect Effects 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- 229940112822 chewing gum Drugs 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 235000014510 cooky Nutrition 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 229960003949 dexpanthenol Drugs 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 235000013681 dietary sucrose Nutrition 0.000 description 1
- MGJZITXUQXWAKY-UHFFFAOYSA-N diphenyl-(2,4,6-trinitrophenyl)iminoazanium Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1N=[N+](C=1C=CC=CC=1)C1=CC=CC=C1 MGJZITXUQXWAKY-UHFFFAOYSA-N 0.000 description 1
- 238000002845 discoloration Methods 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000008157 edible vegetable oil Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000002481 ethanol extraction Methods 0.000 description 1
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000004880 explosion Methods 0.000 description 1
- 201000005577 familial hyperlipidemia Diseases 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000010685 fatty oil Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000019688 fish Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 229940124600 folk medicine Drugs 0.000 description 1
- 239000000576 food coloring agent Substances 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 230000007760 free radical scavenging Effects 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 235000013611 frozen food Nutrition 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 210000004195 gingiva Anatomy 0.000 description 1
- 229960005150 glycerol Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000002132 lysosomal effect Effects 0.000 description 1
- HCWCAKKEBCNQJP-UHFFFAOYSA-N magnesium orthosilicate Chemical compound [Mg+2].[Mg+2].[O-][Si]([O-])([O-])[O-] HCWCAKKEBCNQJP-UHFFFAOYSA-N 0.000 description 1
- 239000000391 magnesium silicate Substances 0.000 description 1
- 229910052919 magnesium silicate Inorganic materials 0.000 description 1
- 235000019792 magnesium silicate Nutrition 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 235000013310 margarine Nutrition 0.000 description 1
- 239000003264 margarine Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 235000013536 miso Nutrition 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 230000004065 mitochondrial dysfunction Effects 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 239000007764 o/w emulsion Substances 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 229940124595 oriental medicine Drugs 0.000 description 1
- 230000004792 oxidative damage Effects 0.000 description 1
- 239000006201 parenteral dosage form Substances 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 229960004063 propylene glycol Drugs 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 235000015067 sauces Nutrition 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 229920002545 silicone oil Polymers 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 231100000438 skin toxicity Toxicity 0.000 description 1
- 229940045902 sodium stearyl fumarate Drugs 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 235000013555 soy sauce Nutrition 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 229960004274 stearic acid Drugs 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 239000000057 synthetic resin Substances 0.000 description 1
- 229920003002 synthetic resin Polymers 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 238000002137 ultrasound extraction Methods 0.000 description 1
- 239000007762 w/o emulsion Substances 0.000 description 1
- 235000012431 wafers Nutrition 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
- 230000037373 wrinkle formation Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/322—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the nervous system or on mental function
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Botany (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Polymers & Plastics (AREA)
- Medicinal Chemistry (AREA)
- Nutrition Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Food Science & Technology (AREA)
- Medical Informatics (AREA)
- Birds (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Cosmetics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention relates to an antioxidative cosmetic composition comprising a purified fraction of red ginseng ethanol extract. By controlling the concentration of ethanol in a desorption solvent used in the production of purified fraction, it is possible to obtain purified red ginseng ethanol fraction having excellent antioxidative effect and high formulation stability Therefore, the purified fraction of the red ginseng ethanol extract according to the present invention can be used for a cosmetic composition, a health supplement food composition and a pharmaceutical composition requiring an antioxidative effect.
Description
The present invention relates to an antioxidant cosmetic composition comprising a purified fraction of red ginseng ethanol extract.
Free radicals and reactive oxygen species are formed by various biological reactions such as normal metabolism by xanthine oxidase or glutathione reductase in mitochondria, phagocytes or cytoplasm, or inflammation reaction by ultraviolet rays and external stimuli. do. In addition to this reactive oxygen species, excessive reactive oxygen species and free radicals, especially superoxide anion radicals, which are highly reactive and destructive, accumulate in the body. In addition to inflammatory reactions, they also cause cell death, stroke, myocardial infarction, , Hyperlipemia, diabetes, neurodegenerative diseases, and various other human diseases. Therefore, it has been reported that the above-mentioned active oxygen or free radical scavenging substances have an effect of preventing or treating these diseases, and researches for developing various active oxygen (or free radical) scavenging substances from microorganisms and plants Is continuing.
On the other hand, Panax Ginseng is a medicinal herb medicine in ginseng and ginseng which has been widely known as a folk medicine as well as oriental medicine. It has been used for a long time as a medicinal material and proved its safety and efficacy. It has been reported that the ginseng has a protective effect against radiation, a chromosome abnormality and micro-nuclear defense effect by an alkylating agent, mutation reduction and cell deformation reduction in cultured cells. In Patent Document 1, a method of increasing the specific ginsenoside with respect to the antioxidative effect of ginseng has been reported.
As described above, it has been reported that the physiological activity exhibited by ginseng is due to a specific ginsenoside. In addition to the effects of individual ginsenosides, studies on the antioxidative effect of specific fractions obtained by fractionating ginseng-derived extracts into columns have been conducted It is not.
The inventors of the present invention examined the fractions exhibiting antioxidative effects by purifying the ginseng-derived extract using a column, and found that fractions obtained by using ethanol as a desorption solvent at a certain concentration as an desorption solvent during purification using a column after ethanol extraction had excellent antioxidative effects The present invention has been completed.
It is an object of the present invention to provide an antioxidant cosmetic composition containing a purified fraction of red ginseng ethanol extract, a health supplement for antioxidation and a pharmaceutical composition for preventing or treating oxidative stress related diseases.
In order to attain the above object, one aspect of the present invention provides an antioxidant cosmetic composition comprising a purified fraction of red ginseng ethanol extract, a health supplement for antioxidation, and a pharmaceutical composition for preventing or treating oxidative stress related diseases.
The term "extract " used in the present invention means a substance extracted from a raw material by an arbitrary method. The extracted extract, the concentrate obtained therefrom, the dried product and the powder of the concentrate are used without limitation.
Hereinafter, the present invention will be described in detail.
One aspect of the present invention provides an antioxidant cosmetic composition comprising purified fractions of red ginseng ethanol extract, a health supplement for antioxidation, and a pharmaceutical composition for preventing or treating oxidative stress related diseases.
The extract may be obtained by extracting from a raw material or a dried product thereof, and the raw material of the extract may be cultivated or commercially available.
When the extract is obtained by extracting from the raw material, any conventional extraction methods known in the art such as a solvent extraction method, an ultrasonic extraction method, a filtration method and a reflux extraction method may be used as the extraction method. Preferably, the extraction method or the reflux extraction method can do. The extraction process can be repeated several times, and then the step such as concentration or freeze-drying can be further roughened. Specifically, the obtained extract is concentrated under reduced pressure to obtain a concentrated liquid, the concentrated liquid is lyophilized, and a concentrated powder can be produced using a pulverizer.
The extract may be extracted using an aqueous solution containing ethanol or ethanol as an extraction solvent, and preferably extracted with an aqueous ethanol solution. The aqueous ethanol solution may be 50 to 70% (v / v), preferably 50 to 65% (v / v), more preferably 50 to 60% (v / v) But not limited thereto. When the concentration of ethanol aqueous solution is less than 50% (v / v), the toxicity is low, but the antioxidative effect is less than that when ethanol is extracted in an appropriate amount. In addition, if it exceeds 70% (v / v), the effect is not improved but toxicity is increased, and there is a risk of explosion due to ethanol vapor particularly during the manufacturing process.
A filler such as silica gel, activated alumina, synthetic polymer, magnesium silicate, activated carbon, cellulose, ion exchange resin and the like may be used as the column used in the production of the purified fraction, and aromatic synthetic resin is preferably used as a filler. More preferably, HP-20 synthetic adsorbent is used as a filler, but is not limited thereto. The separation using the column can be carried out once to several times until the fraction of the desired purity is purified, and concentration and recrystallization can be carried out if necessary.
In the preparation of the purified fraction, the desorption solvent may be an aqueous solution of ethanol, the aqueous ethanol solution may be 5 to 30% (v / v), preferably 5 to 25% (v / v) To 20% (v / v). When the concentration of the aqueous ethanol solution used as the desorption solvent is less than the lower limit value, there is a problem that the obtained antioxidant effect of the obtained fraction is low. When the upper limit is exceeded, the stability of the formulation granules falls when incorporated into the cosmetic composition, and the antioxidative effect is lowered. In addition, when the upper limit is exceeded, the fraction contains a high concentration of ethanol, and when the fraction is added to the antioxidative cosmetic composition without a separate ethanol removal step, skin irritation and toxicity may be caused and the stability of physical properties may be lowered . In order to solve such a problem, when the ethanol is removed through a separate process, the antioxidative effect of the fraction is lowered and the production cost of the raw material is increased due to the addition of the ethanol removal process. Further, the antioxidative effect is excellent when the ethanol aqueous solution is 5 to 30% (v / v), but the fraction obtained by using an aqueous solution of ethanol of more than 20% (v / v) to 30% Is included in the cosmetic composition, the particles may not be formed because the particle stability is lowered. Therefore, the fraction obtained using a 5 to 30% (v / v) ethanol aqueous solution as a desorption solvent can be used for a pharmaceutical composition or a health supplement, and a 5 to 20% (v / v) aqueous ethanol solution is used as a desorption solvent Are suitable for use in cosmetic compositions.
When adding the aqueous ethanol solution, which is a desorption solvent in the production of the purified fraction, an aqueous solution of ethanol is flowed into the column, for example, it is pressurized and flowed.
In one embodiment of the present invention, a red ginseng ethanol extract is prepared by adding an aqueous 55% (v / v) ethanol solution to red ginseng, and the resulting extract is adsorbed on an HP-20 column to adsorb the components adsorbed to the column at various concentrations (V / v) ethanol aqueous solution when the fractions were obtained by desorption using an ethanol solvent (0 (purified water), 5, 10, 20, 30, 50, 95% When the fractions obtained by using as a desorption solvent showed higher antioxidative effect than the red ginseng alcohol extract concentrate and each fraction was added to the emulsifier type cosmetic composition in an amount of 5%, the aqueous ethanol solution of 20% (v / v) or less was dissolved in desorption solvent (See Table 1 and Fig. 1). ≪ tb > < TABLE >
The cosmetic composition according to the present invention can be used for improving skin conditions worsened by action of active oxygen species. More specifically, the present invention relates to a method for preventing or improving damage caused by oxidative damage of the skin such as spot (brown half), freckles, skin cracks, ultraviolet damage (sunburn), wrinkle formation on the skin surface, It can be used for skin aging suppression, skin elasticity retention, skin wrinkle improvement, and skin whitening. Further, since the fraction of the present invention has an antioxidative activity, it can be very usefully used for maintaining the quality of cosmetics by preventing oxidation of the cosmetics themselves.
The purified fraction of the red ginseng ethanol extract may be included in the cosmetic composition having an antioxidative activity in an amount of 0.01 to 40% by weight, preferably 0.01 to 20% by weight. If the content is less than 0.01% by weight, the antioxidative activity may be insignificant. If the content is more than 40% by weight, the antioxidative effect against the input concentration may be relatively low.
In the cosmetic composition of the present invention, the fraction may be prepared into a liquid or a solid form using bases, adjuvants and additives commonly used in the cosmetics field. Liquid or solid cosmetics may include, for example, but not limited to, lotions, creams, lotions, bath salts, and the like.
The base, adjuvant and additives commonly used in the cosmetics field are not particularly limited, and examples thereof include water, alcohol, propylene glycol, stearic acid, glycerol, cetyl alcohol, liquid paraffin and the like.
The present invention also provides a health supplement containing the fraction as an active ingredient.
The health supplement food according to the present invention has excellent antioxidative effect and can be taken to prevent oxidative stress. The fraction is preferably contained in an amount of 0.01 to 10% by weight, more preferably 0.05 to 8% by weight, in the antioxidative effect-enhancing health supplement food of the present invention. If the content is less than 0.01% by weight, the effect of promoting antioxidation of the health supplement may be insignificant. If the content is more than 10% by weight, the effect of enhancing antioxidation may be relatively low.
The kind of the health supplements is not limited. For example, the health supplements may be added to conventional palatable foods such as noodles such as ramen noodles, raw noodles, tofu, cereals, breads, chewing gum, candies, And can be used as a food coloring matter. In addition, it can be formulated into a common formulation such as tablets, granules, pills, hard capsules, soft capsules or liquid formulations, and can be prepared as a juice, a pouch, a drink, or the like. It goes without saying that components other than the above-mentioned components can be appropriately selected and blended by those skilled in the art according to the formulations.
In addition, the fractions contained in the health supplement food of the present invention are excellent in antioxidant activity, and can effectively prevent the change of the smell and flavor of food caused by oxidation, the rancidity of the fat, and the discoloration of food. Therefore, the fractions of the present invention can be used to preserve these foods or to maintain the freshness and quality of foods for a long period of time by blending them into various kinds of ordinary foods.
Such foods include not only typical foods but also beverages (including alcoholic beverages), fruits and processed foods thereof (e.g., canned fruits, bottled, jam, marmalade, etc.), fish, meat and processed foods Etc.), edible vegetable oil (such as butter, chewing), breads and noodles (such as udon, buckwheat noodles, ramen, spaghetti, macaroni, etc.), juice, various drinks, cookies, Margarine, vegetable protein, retort food, frozen food, various seasonings (eg miso, soy sauce, sauces, etc.).
The present invention also provides a pharmaceutical composition for preventing or treating oxidative stress-related diseases comprising the fraction as an active ingredient.
The pharmaceutical composition according to the present invention has excellent antioxidative effect and thus can be applied to diseases related to oxidative stress. Examples of the conditions of oxidative stress related cells include mitochondrial dysfunction, lysosomal and proteasomal dysfunction, oxidation of nucleic acids (e.g., RNA and DNA), initiation of apoptosis, lipid peroxidation and destruction of membrane lipid environment However, this is not the case. The diseases to which the pharmaceutical composition of the present invention can be applied include diseases selected from the group consisting of stroke, myocardial infarction, diabetic vascular disorder, hyperlipidemia, diabetes, epilepsy, Parkinson's disease and dementia, May be used to alleviate the disease or condition caused by active oxygen.
The pharmaceutical composition of the present invention can be administered orally or parenterally. The route of administration of the pharmaceutical compositions of the present invention may be, but is not limited to, oral, intravenous, intramuscular, intraarterial, gingiva, intrathecal, intracardiac, transdermal, subcutaneous, intraperitoneal, , Sublingually or topically.
For such clinical administration, the pharmaceutical composition of the present invention may be formulated into a suitable formulation, such as oral administration, parenteral administration, or injection, using known techniques. For example, upon oral administration, it may be admixed with an inert diluent or edible carrier, sealed in a hard or soft gelatin capsule, or pressed into tablets. For oral administration, the active compound may be formulated as an ingestible tablet, buccal tablets, troches, lozenges, aqueous or oily suspensions, prepared powders or granules, emulsions, suspensions, Hard or soft capsules, elixirs, suspensions, syrups, wafers, and the like. In this case, binders such as lactose, saccharose, sorbitol, mannitol, starch, amylopectin, cellulose or gelatin for formulation into tablets, capsules and the like; Excipients such as dicalcium phosphate; Disintegrating agents such as corn starch or sweet potato starch; Magnesium stearate, calcium stearate, sodium stearyl fumarate, or a lubricant such as polyethylene glycol wax may be mixed. In the case of a capsule formulation, a liquid carrier such as fatty oil may be mixed in addition to the above-mentioned substances.
Parenteral administration is also applied to subcutaneous injections, intravenous injections, intramuscular injections, intra-thoracic injection injections, mucous membranes, or topical application, including dispersing agents, suppositories, powders, aerosols (nasal sprays or inhalants), gels, , Or a non-aqueous liquid suspension, an oil-in-water emulsion or a water-in-oil emulsion), a solution, and the like. For formulation into a parenteral dosage form, the composition may be formulated into a solution by mixing with a stabilizer or buffer in water to form a unit dosage form of ampoule or vial.
The effective dose of the pharmaceutical composition of the present invention as described above can be adjusted to a necessary range according to the clinical judgment in consideration of the patient's age, physical condition, and weight. Generally, the effective dose of the pharmaceutical composition is 1 to 20 mg / day, preferably 5 to 10 mg / day, per 1 kg body weight of an adult patient, Preferably two to five times a day.
The purified fraction of the red ginseng alcohol extract according to the present invention is excellent in antioxidative effect and can be used for a cosmetic composition, a health supplement food composition and a pharmaceutical composition requiring an antioxidative effect because of high formulation stability when added to a cosmetic composition.
1 is a photograph showing the degree of particle formation when purified fraction of red ginseng ethanol extract according to the present invention is added to an emulsifying cosmetic composition.
Hereinafter, the present invention will be described in detail with reference to Production Examples, Examples and Experimental Examples.
However, the following Production Examples, Examples and Experimental Examples are for illustrating the present invention, and the contents of the present invention are not limited by the following Production Examples, Examples and Experimental Examples.
Production of red ginseng extract
1-1. Manufacture of red ginseng water extract
1.5kg of purified water was added to 1kg of red ginseng, and the mixture was extracted three times at 70 ° C for 8 hours. The mixture was centrifuged at low temperature and concentrated under reduced pressure to obtain 50g or more of a red ginseng water extract concentrate having a moisture content of 40%.
1-2. Manufacture of red ginseng ethanol extract
55% (v / v) ethanol was added to 1 kg of red ginseng in 5.5 times and extracted three times at 70 ° C for 8 hours. The extract was extracted with 50 g or more of a red ginseng alcohol extract concentrate having a moisture content of 40% by using a reduced pressure concentrator.
1-3. Purification and fractionation of ethanol extracts
The ethanol extract concentrate obtained in Example 1-2 was placed in an HP-20 column (Mitsubishi Chemical Industry) for adsorption. After removing the unadsorbed portion of the column with purified water, the adsorbed components were adsorbed onto the column using various concentrations of ethanol solvent (0 (purified water), 5, 10, 20, 30, 50, 95% To give a fraction.
Comparison of antioxidative effects of desolvation solvents used in the preparation of purified fractions according to alcohol concentration
The antioxidant activity of the red ginseng water extract, red ginseng ethanol extract, and red ginseng ethanol extract obtained in Example 1 was confirmed by the HP-20 column fraction.
("Stopped-flow and spectrophotometric study on radical scavenging by tea catechins and model compound", Chem Pharm Bull 47: 1369-1374 (1999)) was conducted in order to confirm DPPH radical scavenging ability. 1.5 ml of DPPH dissolved in ethanol, 0.15 ml of the sample and 1.35 ml of distilled water were added thereto so as to have a concentration of 2.0 × 10 -4 M and reacted at 25 ° C. for 30 minutes, and the absorbance was measured at 520 nm. Each sample was prepared at a concentration of 10 mg / ml, the solution was diluted to 1/2 (i.e., 5 mg / ml), the diluted solution was diluted stepwise by 1/2, and diluted to 0.0097 mg / (10, 5, 2.5, 1.25, 0.625, 0.3125, 0.1562, 0.0781, 0.039, 0.0195, 0.0097 mg / ml). L-ascorbic acid was used as a positive control. The antioxidant effect of each sample was evaluated by comparing IC50 value, which is the concentration value when 50% of active oxygen is removed.
As a result, the fractions desorbed with ethanol by adsorbing the red ginseng alcohol concentrate onto the HP-20 column showed antioxidative effect even at a low concentration of IC50 of 1 or less, while the red ginseng water or alcohol extract concentrate had an IC50 value of 1.5 or more Showed antioxidant effect.
In addition, even after the alcohol extraction and purification by HP-20, the antioxidative effect was different depending on the solvent used for desorption. Specifically, when water was used as a solvent, the IC50 value was 2.98, which indicates that the IC50 value was 1.8 times higher than that of the HP-20 column, and thus the antioxidative effect was low. On the other hand, the fraction obtained by using an aqueous ethanol solution as a desorption solvent showed a high antioxidative effect. For example, the fraction obtained using 95% (v / v) ethanol showed 2.32-fold higher antioxidative effect than the red ginseng alcohol extract concentrate. The fraction obtained by using 10 ~ 30% (v / v) ethanol showed the highest antioxidative effect by 4.38 times higher than that of red ginseng alcohol extract. Especially, the fraction obtained by using 10 ~ 20% (v / v) ethanol The antioxidant effect was the best.
The antioxidant activity of the red ginseng concentrate is highly adsorbed on the HP-20 column, and the efficacious ingredient is desorbed most effectively when 10 to 30% ethanol solvent is used, resulting in a fraction having higher antioxidant efficacy. And it was found.
Confirmation of formulation stability of the purified fractions
The formulation stability of each fraction according to the solvent used was confirmed. The fraction obtained in Example 2 was added to the emulsified formulation in an amount of 5% by weight, and the particle state was confirmed by a microscope. The composition of the emulsified formulation is shown in Table 2 below.
As a result, when the ethanol was used as a desorption solvent, the ethanol content of the fraction was high, and the stability of the formulation particle was decreased, and 50% (v / v) ethanol and 95% (v / v) Particles were not formed when used as a desorption solvent, whereas when 5% (v / v) to 20% (v / v) ethanol was used as a desorption solvent, it was confirmed that particle stability was excellent. From the above results, it can be seen that the ethanol fraction having the best antioxidative effect when fractionated with alcohol less than 30% (v / v) and the most stable when using an ethanol fraction having less than 20% (v / v) there was.
Determination of saponin content of extract
In order to confirm whether the fractions of the present invention were caused by saponin, the content of individual ginsenosides contained in the concentrated extract of red ginseng purified water and the extract of red ginseng alcohol obtained in Example 1 was confirmed (Table 3). In addition, the ginsenoside content of the fraction obtained by loading the red ginseng ethanol extract of Example 1 onto the HP-20 column and using various concentrations of aqueous ethanol solution as the desorption solvent was confirmed (Table 4). The content of ginsenoside was measured by HPLC using a conventional test method specified in the Health Functional Food Revision.
Extract concentrate
Extract concentrate
% EtOH fraction
As a result, it was found that the total amount of ginsenosides contained in the extract of the red ginseng alcohol extract was higher than that of the red ginseng purified water extract concentrate (Table 3). In addition, it was found that the higher the ethanol concentration, the greater the total amount of ginsenosides, depending on the ethanol concentration of the desorbing solvent used in the purification using the HP-20 column after alcohol extraction (Table 4).
Although the amount of ginsenoside contained in the concentrated extract of red ginseng alcohol is higher than that of the red ginseng purified water extract, the antioxidative activity of the red ginseng alcohol extract concentrate and the red ginseng purified water extract concentrate are similar in Table 1 of Example 2, It was found that the antioxidative effect of the alcohol extract concentrate was not due to ginsenoside but by other components than ginsenoside. In addition, the amount of ginsenosides increases as the ethanol content of the desolvation solvent is increased to 50% (v / v) in the purified fraction of the red ginseng alcohol concentrate, while the ethanol content of the desolvation solvent is 10-30% (v / v) is the highest, the antioxidative effect of the fraction using the HP-column of the extract of the extract of the red ginseng alcohol of the present invention is not due to the ginsenoside but by the components contained in the fraction.
Claims (12)
Wherein the extraction solvent used in preparing the ethanol extract is an aqueous solution of ethanol.
Wherein the aqueous ethanol solution is 50 to 70% (v / v).
The column used for the preparation of the purified fraction is HP-20.
Wherein the desorption solvent in the preparation of the purified fraction is an aqueous solution of ethanol.
Wherein the aqueous ethanol solution is 5 to 30% (v / v).
Wherein the aqueous ethanol solution is 5 to 25% (v / v).
Wherein the aqueous ethanol solution is 5 to 20% (v / v).
Wherein the cosmetic composition is at least one selected from the group consisting of a skin aging inhibitor, a skin elasticity maintenance agent, a skin wrinkle improving agent and a skin whitening agent.
Wherein said oxidative stress related disease is any one or more diseases selected from the group consisting of stroke, myocardial infarction, diabetic vascular disorder, hyperlipidemia, diabetes, epilepsy, Parkinson's disease and dementia.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020150110187A KR101863694B1 (en) | 2015-08-04 | 2015-08-04 | Cosmetic Composion for Anti-oxidation Containing Purified Extract of Red Ginseng Ethanol Extract |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020150110187A KR101863694B1 (en) | 2015-08-04 | 2015-08-04 | Cosmetic Composion for Anti-oxidation Containing Purified Extract of Red Ginseng Ethanol Extract |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20170016725A true KR20170016725A (en) | 2017-02-14 |
| KR101863694B1 KR101863694B1 (en) | 2018-06-01 |
Family
ID=58121077
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020150110187A KR101863694B1 (en) | 2015-08-04 | 2015-08-04 | Cosmetic Composion for Anti-oxidation Containing Purified Extract of Red Ginseng Ethanol Extract |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR101863694B1 (en) |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107789504A (en) * | 2017-11-27 | 2018-03-13 | 成都中医药大学 | A kind of pharmaceutical composition for treating parkinsonism and its production and use |
| CN107812101A (en) * | 2017-11-15 | 2018-03-20 | 成都图瑞思舟科技有限公司 | One kind treats AED and preparation method |
| CN107898934A (en) * | 2017-09-30 | 2018-04-13 | 张铁臣 | A kind of Chinese prescription for being used to treat epileptics |
| CN108030880A (en) * | 2018-01-26 | 2018-05-15 | 冯玉兴 | A kind of pharmaceutical composition for treating epilepsy, preparation and preparation method thereof |
| KR20210055825A (en) * | 2019-11-07 | 2021-05-18 | 대한민국(농촌진흥청장) | Composition of extracts for antioxidant property containing silk worm pupae and red ginseng |
| KR20230111465A (en) | 2022-01-18 | 2023-07-25 | 주식회사 한국인삼공사 | Composion Comprising Fraction of Ginseng Flower Extract |
| KR20230111466A (en) | 2022-01-18 | 2023-07-25 | 주식회사 한국인삼공사 | Cosmetic Composion for Skin Whitening Comprising Fraction of Ginseng Flower Extract |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20110063912A (en) * | 2009-12-07 | 2011-06-15 | 이정복 | A topical composition comprising the extract of platycodi radix, bupleuri radix and ginseng radix and the purified fractions therefrom inhibiting skin aging and wrinkle formation |
| KR20130075114A (en) * | 2011-12-27 | 2013-07-05 | 주식회사 한국인삼공사 | Method for preparing ginseng liquids containing high quantity of ginsenosides removed pigments and flavor components |
| KR101467837B1 (en) | 2012-11-19 | 2014-12-02 | 재단법인 금산국제인삼약초연구소 | Manufacturing method of fermented red ginseng extract with enhanced ginsenosides Rg3 and antioxidant activity |
-
2015
- 2015-08-04 KR KR1020150110187A patent/KR101863694B1/en active IP Right Grant
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20110063912A (en) * | 2009-12-07 | 2011-06-15 | 이정복 | A topical composition comprising the extract of platycodi radix, bupleuri radix and ginseng radix and the purified fractions therefrom inhibiting skin aging and wrinkle formation |
| KR20130075114A (en) * | 2011-12-27 | 2013-07-05 | 주식회사 한국인삼공사 | Method for preparing ginseng liquids containing high quantity of ginsenosides removed pigments and flavor components |
| KR101467837B1 (en) | 2012-11-19 | 2014-12-02 | 재단법인 금산국제인삼약초연구소 | Manufacturing method of fermented red ginseng extract with enhanced ginsenosides Rg3 and antioxidant activity |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107898934A (en) * | 2017-09-30 | 2018-04-13 | 张铁臣 | A kind of Chinese prescription for being used to treat epileptics |
| CN107812101A (en) * | 2017-11-15 | 2018-03-20 | 成都图瑞思舟科技有限公司 | One kind treats AED and preparation method |
| CN107789504A (en) * | 2017-11-27 | 2018-03-13 | 成都中医药大学 | A kind of pharmaceutical composition for treating parkinsonism and its production and use |
| CN108030880A (en) * | 2018-01-26 | 2018-05-15 | 冯玉兴 | A kind of pharmaceutical composition for treating epilepsy, preparation and preparation method thereof |
| CN108030880B (en) * | 2018-01-26 | 2020-10-23 | 冯玉兴 | Pharmaceutical composition and preparation for treating epilepsy and preparation method thereof |
| KR20210055825A (en) * | 2019-11-07 | 2021-05-18 | 대한민국(농촌진흥청장) | Composition of extracts for antioxidant property containing silk worm pupae and red ginseng |
| KR20230111465A (en) | 2022-01-18 | 2023-07-25 | 주식회사 한국인삼공사 | Composion Comprising Fraction of Ginseng Flower Extract |
| KR20230111466A (en) | 2022-01-18 | 2023-07-25 | 주식회사 한국인삼공사 | Cosmetic Composion for Skin Whitening Comprising Fraction of Ginseng Flower Extract |
Also Published As
| Publication number | Publication date |
|---|---|
| KR101863694B1 (en) | 2018-06-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101863694B1 (en) | Cosmetic Composion for Anti-oxidation Containing Purified Extract of Red Ginseng Ethanol Extract | |
| JP5937596B2 (en) | Urushi extract with increased content of active flavonoid compound and method for producing the same | |
| KR101577111B1 (en) | Pharmaceutical compositions for anti-inflammation or anti-oxidation containing ginsenoside rh4-enriched extraction | |
| WO2012121140A1 (en) | Growth hormone secretion promoter | |
| JP6751709B2 (en) | Energy metabolism activator in muscle cells | |
| KR101816401B1 (en) | Composition for Anti-oxidation Containing Purified Fraction of Ginseng berry Extract | |
| KR101976260B1 (en) | Method of Preparing Red-Ginseng Vinegar | |
| JP2006016387A (en) | New royal jelly formulation | |
| JP2022169695A (en) | Brain-dysfunction preventing and/or improving composition containing lutein or salt thereof and processed product of plant belonging to genus trapa | |
| JP2006193502A (en) | Adiponectin regulating agent and food, drink, food additive and medicine containing the same | |
| JP2010095529A (en) | Composition for improving lipid metabolism | |
| JP2009298769A (en) | Fat accumulation-suppressing composition | |
| KR102161179B1 (en) | Antioxidative composition comprising extract of red tea stem | |
| JP2005015364A (en) | Anti-oxidizing composition, skin ageing-preventing composition, anti-inflammatory composition and lipid metabolism-improving composition | |
| KR101188581B1 (en) | Composition comprising Cyperus rotundus methalnol extracts for preventing or treating Sepsis | |
| EP2089505A1 (en) | Reduced-hangover alcoholic beverage | |
| KR20150058698A (en) | Antioxidant composition containing purified bee venom | |
| JP2006347975A (en) | Oral composition for cardiovascular disease prophylaxis and amelioration | |
| KR101532484B1 (en) | Cosmetic compositions for anti-inflammation or anti-oxidation containing ginsenoside rh4-enriched extraction | |
| WO2006064761A1 (en) | Adiponectin regultor and foods, drinks, food aditives and drugs containing the same | |
| KR20150113709A (en) | Skin whitening composition containing Allium hookeri extract | |
| US20220160810A1 (en) | Methods for continuous extraction and purification of a unique flavan-3-ol extract from immature whole grape clusters and compositions thereof | |
| KR101689267B1 (en) | Cosmetic composition for preventing or improving skin wrinkle comprising mixture of red ginseng extract and astaxanthin as effective component | |
| KR100787765B1 (en) | Composition comprising palmitic acid for preventing or treating alzheimer's disease | |
| KR101576916B1 (en) | Compositon containing sulfuretin for treatment or improvement of dental diseases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| E902 | Notification of reason for refusal | ||
| AMND | Amendment | ||
| E601 | Decision to refuse application | ||
| AMND | Amendment | ||
| E902 | Notification of reason for refusal | ||
| AMND | Amendment | ||
| X701 | Decision to grant (after re-examination) | ||
| GRNT | Written decision to grant |